Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Swiss to get Moderna vaccine in tranches until mid-year - Blick

01/17/2021 | 03:55am EST

ZURICH, Jan 17 (Reuters) - Moderna will deliver 7.5 million doses of COVID-19 vaccine to Switzerland in batches in the months ahead, putting the country among the world leaders in inoculating its population, the head of Moderna's European business said.

"We are working at full speed to steadily expand our production capacities. If everything goes as planned, just under half the population could be treated with our vaccine by the summer," Dan Staner told the SonntagsBlick newspaper in an interview.

Staner said Switzerland would not get privileged treatment because it was the first country to chose Moderna as a supplier.

"Every country deserves equal treatment. We refrain from stockpiling vaccines and delivering them only when a country orders them. Every dose that is produced is delivered immediately, according to the contract," he said.

"People are suffering in the same way all over the world. In times like these no one deserves special treatment."

Swiss regulators have approved vaccines from Moderna and from Pfizer with partner BioNTech. They are still reviewing a vaccine from AstraZeneca.

Switzerland, with a population of 8.6 million, has ordered 15 million vaccine doses in total after setting aside 400 million Swiss francs ($449 million) for shots.

($1 = 0.8907 Swiss francs) (Reporting by Michael Shields; Editing by Toby Chopra)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.93% 6945 Delayed Quote.-5.17%
BIONTECH SE -2.94% 109.03 Delayed Quote.33.75%
MODERNA, INC. 4.33% 154.81 Delayed Quote.48.19%
PFIZER INC. -0.98% 33.49 Delayed Quote.-8.12%
All news about MODERNA, INC.
02/26Panel urges US regulators to approve single-dose Covid-19 vaccine
AQ
02/26J&J Single-Dose Covid-19 Vaccine Gains Backing From FDA Advisory Panel -- 4th..
DJ
02/26J&J Single-Dose Covid-19 Vaccine Gains Backing From FDA Advisory Panel -- 3rd..
DJ
02/26Health Care Down On Growth Doubts -- Health Care Roundup
DJ
02/26MODERNA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
02/26PFIZER : Scammers Are Setting Up Fake Covid Vaccine Websites
DJ
02/26MARKET CHATTER : Johnson & Johnson Says COVID-19 Vaccine Tied to Severe Allergic..
MT
02/26MODERNA : U.S. administers 70.5 mln doses of COVID-19 vaccines - CDC
RE
02/26FDA advisory panel to review Johnson & Johnson COVID-19 vaccine with thumbs u..
RE
02/26MODERNA : JP Morgan Adjusts Moderna's Price Target to $121 From $89, Maintains N..
MT
More news
Financials (USD)
Sales 2020 502 M - -
Net income 2020 -582 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -124x
Yield 2020 -
Capitalization 61 260 M 61 260 M -
EV / Sales 2020 117x
EV / Sales 2021 2,97x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 162,14 $
Last Close Price 154,81 $
Spread / Highest target 34,4%
Spread / Average Target 4,74%
Spread / Lowest Target -48,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.48.19%61 260
LONZA GROUP AG0.88%46 924
IQVIA HOLDINGS INC.7.60%36 877
CELLTRION, INC.-17.13%35 993
SEAGEN INC.-13.72%27 376
HANGZHOU TIGERMED CONSULTING CO.,LTD-13.01%18 684